Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Characterization of the PKPD relationship of reduced cholesterolemia by the peptide PCSK9-LDL receptor protein-protein interaction inhibitor P7 in mice and non-human primates
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-067-Monday
- By: BUETERS, Tjerk (Merck & Co, Inc, PPDM, Westpoint, United States)
- Co-author(s): Tjerk Bueters: PPDM, Merck & Co, Inc, Westpoint, PA, United States
Kenneth Koeplinger: PPDM, Merck & Co, Inc, Westpoint, PA, United States
Philippe Costet: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
Beth Murphy: Department of In Vivo Pharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
Scott Salowe: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
Hratch Zokian: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
Michael Kavana: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
Candice Alleyne: Department of Discovery Pharmaceutical Sciences, Merck & Co, Inc, Kenilworth, NJ, United States
Annette Bak: Department of Discovery Pharmaceutical Sciences, Merck & Co, Inc, Kenilworth, NJ, United States
Sheng-Ping Wang: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
Yongcheng Huang: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
Angela Kerekes: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
James Tata: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
Yusheng Xiong: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
Shirly Pinto: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States - Abstract:
Backgrounds
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a clinically and genetically validated target to effectively reduce elevated LDL-c levels. Anti-PCSK9 antibody therapies (Repatha/Amgen, Praluent/Sanofi-Regeneron) have recently been approved as adjunct to diet and maximally tolerated statin therapy for patients suffering from.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023